Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 19/20 | 0.66 |
| ▸ | MMP9 | P14780 | 19/20 | 0.66 |
| ▸ | MMP3 | P08254 | 3/20 | 0.66 |
| ▸ | MMP8 | P22894 | 3/20 | 0.66 |
| ▸ | MMP13 | P45452 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924484 | 0.86 | MMP2 (0.59) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL5924511 | 0.85 | MMP2 (0.53) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL5924506 | 0.85 | MMP2 (0.51) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL4038795 | 0.83 | MMP9 (0.57) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL4662863 | 0.80 | MMP2 (0.57) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL4321603 | 0.79 | MMP2 (1.00) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL7472025 | 0.79 | MMP2 (0.47) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6810540 | 0.76 | MMP2 (1.00) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6594332 | 0.73 | MMP2 (0.79) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL7383539 | 0.73 | MMP2 (0.70) | MMP2MMP9MMP3MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1318406-C | New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same | BOEHRINGER MANNHEIM GMBH (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6716845-B2 | Barbituric acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1383746-A2 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-28 | — | — | EP | disclosed |
| US-6498252-B1 | Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | HOFFMANN-LA ROCHE INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020187991-A1 | Barbituric acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| US-6472396-B1 | Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| EP-0869947-B1 | BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002079170-A2 | PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| EP-1226128-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001025217-A1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-12 | — | — | WO | disclosed |
| US-6110924-A | MATRIX METALLOPROTEASE INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-08-29 | — | — | US | disclosed |
| CN-1209123-A | New barbituric acid derivatives, processes for their prodn. and pharmaceutical agent contg. same | BOEHRINGER MANNHEIM GMBH (DE) | 1999-02-24 | — | — | CN | disclosed |
| EP-0869947-A1 | NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023465-A1 | NEW BARBITURIC ACID DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187991-A1 | Barbituric acid derivatives | GABBR1, GABBR2, TUBB6 | MMP2 2685/4885MMP9 2795/4885MMP3 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.